Clinical trials: Digestive System Cancer
Esophageal Squamous Cell Carcinoma
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04063683
- Testing
- Anlotinib Hydrochloride, Paclitaxel, cisplatin
- Where
- 6 sites in China
- Volunteers
- 47 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancers, Esophagogastric Junction Cancers
QL1706 Combined With SOX Used in Theperioperative Treatment
This is a single-center, single-arm clinical study to evaluate the efficacy and safety of QL1706 combined with SOX for the treatment of resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT06766305
- Testing
- QL1706 combined with SOX
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Xiangdong Cheng
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Lidocaine for Oxaliplatin-induced Neuropathy
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen.
- Conditions
- Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
- Trial name
- NCT03254394
- Testing
- Lidocaine Hydrochloride, FOLFOX regimen
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Gastric Cancer
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05678205
- Testing
- AB-201, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States, South Korea
- Sponsor
- Artiva Biotherapeutics, Inc.
Esophageal Cancer
Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial
For patients who are unable to receive surgery or having local advanced esophageal cancer stages, concurrent chemoradiotherapy is recommended.
- Trial name
- NCT01463605
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Chinese Academy of Medical Sciences
Colon Carcinoma, Barrett Esophagus
Safety and Feasibility of Immuno-OCT
To improve detection of premalignant lesions in the gastrointestinal tract (the rectum and the esophagus) there is a need for better endoscopic visualization and the ability for targeted biopsies.
- Conditions
- Colon Carcinoma, Barrett Esophagus, Gastrointestinal Dysplasia
- Trial name
- DETOUR (NCT06008522)
- Testing
- Bevacizumab-800CW
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Gastric Cancer
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT02525237
- Testing
- Apatinib, S-1
- Volunteers
- 30 people
- Sponsor
- Qingdao Municipal Hospital
Colonic Neoplasms
Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology
This three parallel-arms, randomized, multicenter trial is aimed at investigating the value of AI-assisted optical biopsy for differentiating between neoplastic and non-neoplastic polyps which will lead to the implementation of…
- Trial name
- SAVE (NCT06041945)
- Testing
- Standard, high-definition colonoscopy with the use of CADe assistance, Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ, Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ
- Where
- 2 sites in Italy
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Colorectal Cancer, Pancreatic Cancer
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
This clinical trial will utilize a neoantigen nanovaccine constructed from the bacterial membranes of an engineered Lactococcus lactis strain (FOLactis).
- Trial name
- NCT07353645
- Testing
- KRAS Neoantigen Nanovaccine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreas Cancer, Relapse
Autologous CAR-T Cells Targeting B7-H3 in PDAC
The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in…
- Conditions
- Pancreas Cancer, Relapse, Resistant Cancer
- Trial name
- NCT06158139
- Testing
- iC9-CAR.B7-H3 T cell infusion
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
To determine the efficacy and toxicity of TACE combined with SBRT
- Conditions
- Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
- Trial name
- NCT01020812
- Testing
- TACE, SBRT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Colorectal Cancer (CRC)
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
This phase II, single-arm clinical study aims to evaluate the efficacy and safety of toripalimab combined with cetuximab and irinotecan as second-line treatment for patients with advanced right-sided colon cancer with wild-type…
- Trial name
- NCT07896681
- Testing
- Toripalimab, Cetuximab, Irinotecan
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Peritoneal Carcinoma, Colorectal Carcinoma
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
This is a phase 1/2a open label study to evaluate the dose, safety, tolerability and efficacy of an IP α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC) from colorectal carcinoma…
- Trial name
- NCT03732781
- Testing
- Radspherin
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 47 people
- Sponsor
- Oncoinvent Solutions AS
Gastrointestinal Cancer, Gastrointestinal Neoplasms
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms
- Trial name
- NCT03597581
- Testing
- ompenaclid, FOLFIRI, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 89 people
- Sponsor
- Inspirna, Inc.
Esophageal Cancer
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab.
- Trial name
- NCT06718205
- Testing
- Nimotuzumab, Sintilimab, Paclitaxel-albumin
- Where
- China
- Volunteers
- 112 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Solid Tumor, High-Risk Cancer
A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia…
- Conditions
- Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer
- Trial name
- Def_Special (NCT04905329)
- Testing
- Empegfilgrastim
- Where
- 3 sites in Russia
- Volunteers
- 285 people
- Sponsor
- Moscow Clinical Scientific Center
Rectal Cancer
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
Why is this study conducted? The purpose of this study is to improve the treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer…
- Trial name
- STARS-RC10 (NCT07505472)
- Testing
- Experimental Group, Control group
- Where
- China
- Volunteers
- 212 people
- Sponsor
- The First Hospital of Jilin University
Biliary Tract Cancer, Radiotherapy
COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer
The study is a single-arm, phase II trial. The purpose is to investigate both the efficacy and safety of radiotherapy combined with anti-PD-1 antibody in unresectable biliary tract cancer patients.
- Conditions
- Biliary Tract Cancer, Radiotherapy, Immunotherapy
- Trial name
- CORRECT (NCT03898895)
- Testing
- Radiotherapy+anti-PD-1 antibody
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Neoadjuvant Therapy
Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI
This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as…
- Trial name
- NCT06833775
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.